Insider Trading Alert - BMRN, RFMD And KOS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 4, 2014, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $287.50 to $28,284,584.53.

Highlighted Stocks Traded by Insiders:

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Spiegelman Daniel K, who is EVP, Chief Financial Officer at Biomarin Pharmaceutical, sold 2,229 shares at $61.76 on Aug. 4, 2014. Following this transaction, the EVP, Chief Financial Officer owned 68,676 shares meaning that the stake was reduced by 3.14% with the 2,229-share transaction.

The shares most recently traded at $65.12, up $3.37, or 5.17% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 2,229
  • 12-Week # shares sold: 9,086
  • 24-Week # shares sold: 14,567

The average volume for Biomarin Pharmaceutical has been 1.2 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $9.1 billion and is part of the health care sector and drugs industry. Shares are down 11.94% year-to-date as of the close of trading on Monday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RF Micro Devices (RFMD) - FREE Research Report

Creviston Steven E, who is VP and Pres. Cellular Products at RF Micro Devices, sold 25,000 shares at $11.21 on Aug. 4, 2014. Following this transaction, the VP and Pres. Cellular Products owned 1.0 million shares meaning that the stake was reduced by 2.36% with the 25,000-share transaction.

Hilgendorf Norman A, who is VP & Pres. Multi-Market Prod. at RF Micro Devices, sold 10,000 shares at $11.24 on Aug. 4, 2014. Following this transaction, the VP & Pres. Multi-Market Prod. owned 307,312 shares meaning that the stake was reduced by 3.15% with the 10,000-share transaction.

The shares most recently traded at $11.23, down $0.01, or 0.05% since the insider transaction. Historical insider transactions for RF Micro Devices go as follows:

  • 4-Week # shares sold: 50,000
  • 12-Week # shares sold: 384,080
  • 24-Week # shares sold: 796,011

The average volume for RF Micro Devices has been 10.5 million shares per day over the past 30 days. RF Micro Devices has a market cap of $3.3 billion and is part of the technology sector and electronics industry. Shares are up 122.29% year-to-date as of the close of trading on Monday.

RF Micro Devices, Inc. is engaged in the design, development, manufacture, and marketing of radio frequency (RF) solutions for original equipment manufacturers and original design manufacturers in wireless and wired communications applications in the United States and internationally. The company has a P/E ratio of 284.8. Currently, there are 8 analysts who rate RF Micro Devices a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RFMD - FREE

TheStreet Quant Ratings rates RF Micro Devices as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full RF Micro Devices Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Kosmos Energy (KOS) - FREE Research Report

Hayes William S, who is SVP, Government Affairs at Kosmos Energy, sold 4,000 shares at $9.52 on Aug. 4, 2014. Following this transaction, the SVP, Government Affairs owned 1.3 million shares meaning that the stake was reduced by 0.32% with the 4,000-share transaction.

The shares most recently traded at $9.67, up $0.15, or 1.55% since the insider transaction. Historical insider transactions for Kosmos Energy go as follows:

  • 4-Week # shares sold: 10.4 million
  • 12-Week # shares sold: 10.7 million
  • 24-Week # shares sold: 11.9 million

The average volume for Kosmos Energy has been 1.2 million shares per day over the past 30 days. Kosmos Energy has a market cap of $3.6 billion and is part of the basic materials sector and energy industry. Shares are down 13.42% year-to-date as of the close of trading on Monday.

Kosmos Energy Ltd. explores and produces oil and gas in Africa, Europe, and South America. Its asset portfolio includes production and other projects offshore Ghana, as well as exploration licenses with hydrocarbon potential offshore Ireland, Mauritania, Morocco, and Suriname. The stock currently has a dividend yield of 7.1%. Currently, there are 3 analysts who rate Kosmos Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KOS - FREE

TheStreet Quant Ratings rates Kosmos Energy as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Kosmos Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries